Analysts anticipate Roivant Sciences to report an earnings per share (EPS) of $-0.16. The announcement from Roivant Sciences is eagerly anticipated, with investors seeking news of surpassing estimates ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price target the same at $18. The reiteration comes after the company appointed ...

Wednesday closed down -0.56%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.58%, and the Nasdaq 100 Index ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas ...

Entrepreneur and politician Vivek Ramaswamy made much of his fortune founding biotechnology companies and trading their stocks, but now the former GOP presidential candidate and current contender for ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against David Einhorn's other stock picks with huge upside potential. David Einhorn is a widely ...